Patents by Inventor Yingjun Zhang

Yingjun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210101882
    Abstract: A class of fluorine-substituted indazole compounds and uses thereof, further to pharmaceutical compositions containing these compounds. The compounds and pharmaceutical compositions of the invention can be used as soluble guanylate cyclase simulators.
    Type: Application
    Filed: April 10, 2018
    Publication date: April 8, 2021
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Yinglin ZUO, Xiaojun WANG, Chuanwen YANG, Jiancheng WANG, Shengtian CAO, Fangyuan WU, Yingjun ZHANG, Siegfried GOLDMANN
  • Patent number: 10966970
    Abstract: A fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The compound also includes a Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.
    Type: Grant
    Filed: June 2, 2018
    Date of Patent: April 6, 2021
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinchang Liu, Qingyun Ren, Jianzhou Huang, Zhimin Xiong, Jinfeng Xiong, You Li, Yang Liu, Zhifu Zou, Guanghua Yan, Siegfried Goldmann, Yingjun Zhang
  • Publication number: 20210061839
    Abstract: A glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.
    Type: Application
    Filed: January 22, 2019
    Publication date: March 4, 2021
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng GU, Wuyong WU, Tong QU, Panpan KANG, Zongyuan ZHANG, Weiming HUANG, Jianyu LIU, Yingjun ZHANG
  • Publication number: 20210054013
    Abstract: A glucopyranosyl derivative is used as an inhibitor of sodium-dependent glucose transporters (SGLTs), particularly being used as an inhibitor of sodium-dependent glucose transporter-1 (SGLT1), and a pharmaceutically acceptable salt or stereoisomer thereof, further relating to a pharmaceutical composition containing the derivative. The compound and a pharmaceutical composition is used thereof in the preparation of a drug for treating diabetes and diabetes-related diseases.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 25, 2021
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng GU, Wuyong WU, Panpan KANG, Tong QU, Zongyuan ZHANG, Weiming HUANG, Tianyun WU, Yingjun ZHANG
  • Publication number: 20210053918
    Abstract: A pyrrolidineamide derivatives and uses thereof, specifically, the present invention relates to a novel pyrrolidineamide compound and a pharmaceutical composition containing this compound, which can be used as a MAO-B inhibitor. The present invention also relates to methods of preparing this compound and pharmaceutical composition, and their use in the manufacture of a medicament for treating a disease regulated by MAO-B comprising a neurodegenerative disease, especially Parkinson's disease.
    Type: Application
    Filed: March 7, 2019
    Publication date: February 25, 2021
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Chuanfei JIN, Kangzhi CHEN, Yingjun ZHANG
  • Patent number: 10927118
    Abstract: A class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 23, 2021
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Changhua Tang, Qingyun Ren, Junjun Yin, Kai Yi, Yibo Lei, Yejun Wang, Yingjun Zhang
  • Publication number: 20210047341
    Abstract: Disclosed are a sesquiterpene derivative and a use of the same in preparation of a medicament for treating hepatitis B diseases. The sesquiterpene derivative has the effects of down-regulating the hepatocyte nuclear factor 4? (HNF-4?) and significantly inhibiting the hepatitis B virus, and can be used for preventing and/or treating and/or assisting in the treatment of liver system diseases and symptoms caused by the hepatitis B virus, and can be used as a hepatic protective agent. In addition, the synthetic sesquiterpene derivative can also be used for preventing or treating viral infectious diseases and conditions resulting from the influenza virus, coxsackievirus, herpes simplex virus, etc. Also involved is the preparation of the synthetic sesquiterpene derivative, which acts as a raw material, in clinically acceptable pharmaceutical formulations, such as oral dosage forms such as tablets, capsules and drop pills or non-oral dosage forms such as inhalants and injections.
    Type: Application
    Filed: February 26, 2019
    Publication date: February 18, 2021
    Inventors: Min XU, Haoyang YUAN, Haizhou LI, Yingjun ZHANG, Chongren YANG
  • Publication number: 20200392146
    Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.
    Type: Application
    Filed: January 28, 2019
    Publication date: December 17, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinye YANG, Xiaojun WANG, Junwen WU, Hong CHEN, Shengtian CAO, Yingjun ZHANG
  • Publication number: 20200377461
    Abstract: An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.
    Type: Application
    Filed: December 28, 2018
    Publication date: December 3, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng GU, Jianhao LI, Zheng LI, Weihua WANG, Haoxiong QIN, Xuli WANG, Jianyu LIU, Yingjun ZHANG
  • Patent number: 10851068
    Abstract: A method for preparing a pyrimidone compound and an important intermediate in which raw materials of the preparation method are cheap, the reaction condition of preparation method is mild, the preparation method is simple to operate, and is safe and controllable, has high total yield, and thus is suitable for industrial production.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: December 1, 2020
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Runfeng Lin, Xiaojun Wang, Jihua Lin, Liang Chen, Yingjun Zhang, Jiancun Zhang
  • Publication number: 20200339564
    Abstract: Provided herein is inhibitors of influenza virus replication and uses thereof. Specifically, provided herein a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Application
    Filed: January 4, 2018
    Publication date: October 29, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun REN, Changhua TANG, Junjun YIN, Kai YI, Yibo LEI, Yejun WANG, Yingjun ZHANG
  • Publication number: 20200299294
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Application
    Filed: June 9, 2020
    Publication date: September 24, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Qingyun REN, Changhua TANG, Xiaohong LIN, Junjun YIN, Kai YI
  • Publication number: 20200283454
    Abstract: Disclosed are a compound as shown in formula (I) as an influenza virus replication inhibitor and a preparation method therefor, a pharmaceutical composition comprising the compound and the use of the compound and pharmaceutical composition thereof in the treatment of influenza.
    Type: Application
    Filed: September 18, 2018
    Publication date: September 10, 2020
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Changhua TANG, Qingyun REN, Huichao LUO, Junjun YIN, Kai YI, Yibo LEI, Yejun WANG, Yingjun ZHANG
  • Publication number: 20200283445
    Abstract: A dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B, specifically, is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification; and also includes the use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.
    Type: Application
    Filed: October 17, 2018
    Publication date: September 10, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinchang LIU, Qingyun REN, Guanghua YAN, Siegfried GOLDMANN, Yingjun ZHANG
  • Publication number: 20200276196
    Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.
    Type: Application
    Filed: September 21, 2018
    Publication date: September 3, 2020
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Chuanfei JIN, Wenhe ZHONG, Haiping LIANG, Yingjun ZHANG
  • Patent number: 10759812
    Abstract: The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: September 1, 2020
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Wanjun Tang, Xinye Yang, Zheng Gu, Chenlu Li, Zongyuan Zhang, Zhifu Wan, Xiaojun Wang, Yingjun Zhang
  • Patent number: 10717732
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 21, 2020
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Qingyun Ren, Changhua Tang, Xiaohong Lin, Junjun Yin, Kai Yi
  • Publication number: 20200157054
    Abstract: A method for preparing a pyrimidone compound and an important intermediate in which raw materials of the preparation method are cheap, the reaction condition of preparation method is mild, the preparation method is simple to operate, and is safe and controllable, has high total yield, and thus is suitable for industrial production.
    Type: Application
    Filed: July 3, 2018
    Publication date: May 21, 2020
    Applicant: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Runfeng LIN, Xiaojun WANG, Jihua LIN, Liang CHEN, Yingjun ZHANG, Jiancun ZHANG
  • Patent number: 10647682
    Abstract: Provided are salts of 2,6-dimethylpyrimidone derivatives and uses thereof. Also provided are pharmaceutical compositions containing the salts.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: May 12, 2020
    Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Runfeng Lin, Liang Chen, Xiaojun Wang, Yingjun Zhang, Jiancun Zhang
  • Patent number: 10647693
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the manufacture of medicaments for treating of influenza.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 12, 2020
    Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Changhua Tang, Qingyun Ren, Junjun Yin, Kai Yi, Yingjun Zhang